Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | Outperform → Market Perform | TD Cowen | |
| 11/8/2022 | $9.00 | Buy | Canaccord Genuity |
| 12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $50.00 → $27.00 | Buy | Needham |
| 12/14/2021 | Outperform → Mkt Perform | William Blair |
Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it
Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
S-8 - Generation Bio Co. (0001733294) (Filer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery syste
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is a biotechnology company working to chan
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a
TD Cowen downgraded Generation Bio from Outperform to Market Perform
Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00
JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously